Cancer of the Prostate
Conditions
Brief summary
The purpose of this research study is to investigate the utility of a validated urine test which predicts the likelihood of high grade prostate cancer on an initial prostate biopsy.
Detailed description
Primary Objective(s) 1. Evaluate performance of the ExoDx Prostate(IntelliScore) (EPI) to reduce the number of initial prostate biopsies by greater than or equal to 15% for men with an elevated Prostate-Specific Antigen 2-10ng/mL presenting for a biopsy in consultation with their urologist. 2. Compare performance of both the ExoDx Prostate(IntelliScore) 15.6 and 20 cut-points with respect to the biopsy decision process. 3. Assess physician satisfaction with the ExoDx Prostate(IntelliScore) report including test result presentation, graphics and interpretation. 4. Assess urologist / patient satisfaction for ease of understanding test results and role on biopsy decision process. Secondary Objectives 1. Determine the medical economic impact of the ExoDx Prostate(IntelliScore) test in the prostate biopsy decision process. 2. Correlation of the ExoDx Prostate(IntelliScore) score with the actual biopsy result by utilizing the Receiver Operating Characteristic of the Area Under Curve for discriminating high-grade (greater than or equal to Gleason Score 7, International Society of Urological Pathology 2 and 3) from low-grade (Gleason Score 6, International Society of Urological Pathology 1) and benign disease on initial prostate needle biopsy.
Interventions
DIAGNOSTIC_TESTExoDx Prostate (IntelliScore)
ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
Sponsors
CareFirst BlueCross BlueShield
Chesapeake Urology Research Associates
Exosome Diagnostics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
TRIPLE (Subject, Caregiver, Investigator)
Intervention model description
This is a prospective, randomized blinded, shared decision-impact and health-economic assessment study. 1000 appropriately screened consecutive patients seen during planning for a prostate biopsy will be enrolled. 500 patients will be randomized (blinded) to have the ExoDx Prostate (IntelliScore) test (Cohort A) and 500 (Cohort B) will proceed with conventional standard of care. At time of enrollment, neither the patient nor the urologist will be made aware of whether the patient will have an ExoDx Prostate (IntelliScore) test as part of their work-up. Cohort A EPI test results will be sent to the urologist for assessment and ultimately shared with the patient.
Eligibility
Sex/Gender
MALE
Age
50 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* 50 years of age * Clinical suspicion for prostate cancer * Elevated Prostate-specific antigen between: 2.0 - 10 ng/ mL * No clinical history of a prior negative biopsy
Exclusion criteria
* History of prior prostate biopsy. * Use of medications or hormones that are known to affect serum Prostate-specific antigen levels within 3-6 months of study enrollment. * Clinical symptoms of urinary tract infection (including prostatitis) at the time of enrollment. * History of prostate cancer. * History of invasive treatments for benign prostatic hypertrophy (Benign Prostatic Hyperplasia) or lower urinary track symptoms within 6 months of study enrollment. * Known hepatitis (all types) and/or HIV documented in patient's medical record. * Patients with history of concurrent renal/bladder tumors.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate performance of the ExoDx Prostate(IntelliScore) | 6 Months | Evaluate performance of the ExoDx Prostate(IntelliScore) to reduce the number of initial prostate biopsies by greater than or equal to 15% for men with an elevated prostate specific antigen between 2-10ng/mL presenting for a biopsy in consultation with their urologist. |
Countries
United States
Outcome results
None listed